Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Innovaciones terapéuticas para enfermedades del sistema nervioso con necesidades médicas sin cubrir

Resumen

Tipo:
Demanda Tecnológica
Referencia:
TRFR20170905001
Publicado:
02/10/2017
Caducidad:
02/10/2018
Resumen:
Una empresa francesa de parafarmacia está especializada en desarrollar tratamientos innovadores para enfermedades del sistema nervioso con necesidades médicas sin cubrir, especialmente alteraciones metabólicas de enfermedades del sistema nervioso central. Dentro de este marco de desarrollo, la empresa busca nuevos activos para su catálogo en el campo de trastornos neurológicos. El objetivo es establecer acuerdos de licencia, investigación y joint venture con socios industriales y académicos.

Details

Tittle:
Therapeutic innovations for diseases of the nervous system with high unmet medical needs
Summary:
A French pharmaceutical company is specialized in developing innovative treatments for diseases of the nervous system with high unmet medical needs. Within the frame of its development as fully integrated pharmaceutical company, it is currently looking for new assets for its portfolio in the field of neurological disorders. This company is considering license and/or research cooperation agreement as well as joint-venture agreement.
Description:
A French pharmaceutical company specialized in neurological diseases with high unmet medical needs. Its core focus lies on the metabolic alterations of central nervous system diseases as novel therapeutic approach.

The company´s pipeline is currently composed of one molecule that has successfully finished phase III, two further compounds in late preclinical development and they have their own research platform to identify further promising therapeutic targets.

Within the frame of their development as fully integrated pharmaceutical company, it is now looking for new assets for the extension of its portfolio in the field of central nervous system disorders with high unmet medical needs. It is interested in new best- or first-in-class assets (new chemical entity, biologicals, repurposed drugs) preferentially targeting brain metabolism from early developmental stages (drug discovery) to late clinical phases. With its track record of successfully developed molecules and its expertise to progress the development of drugs from discovery to commercialisation, it is able to provide new treatment solutions for patients in need.

The French company is flexible concerning deal structure and is opened to different types of partnerships including in-licensing, co-development, research and development collaboration or sponsored research with both industrial and academic partners.
Technical Specification or Expertise Sought:
Research institutes, hospital or biotechnological and pharmaceutical companies with therapeutic assets that are looking for a partner to develop the molecules through preclinical and clinical stages towards commercialisation.

Partner sought

Type and Role of Partner Sought:
Industrial and academic partners, open for licensing, co-development, sponsored research with a pharmaceutical company

Client

Type and Size of Client:
Industry SME 50-249
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
French
German
Italian